CAMBRIDGE, Mass., Aug. 25, 2022 -- Aktis Oncology, a biotechnology company discovering and developing novel classes of targeted alpha radiopharmaceuticals to treat a broad range of solid tumors, today announced...
Thrasos Completes Enrollment of Phase 2 THR-184 Clinical Study for Acute Kidney Injury
News | 07. 08. 2015
Thrasos Therapeutics
MONTREAL, July 7, 2015 – Thrasos Therapeutics, a biotherapeutics company focused on delivering new solutions for kidney disease, announced the completion of enrollment in its Phase 2 clinical study of THR-184 for the prevention of acute kidney injury (AKI) in “at risk” patients undergoing cardiac surgery. Results from the 452-patient study are expected by January 2016.
